About this trial
This study will compare two different sedation approaches used during gastroscopy, colonoscopy, and endoscopic retrograde cholangiopancreatography (ERCP). One group will receive dexmedetomidine alone (opioid-free sedation), while the other group will receive dexmedetomidine combined with remifentanil (opioid-based sedation).
The purpose of the study is to determine whether an opioid-free sedation approach can reduce opioid-related adverse symptoms, such as nausea, vomiting, dizziness, drowsiness, dry mouth, headache, and fatigue. The study will also evaluate quality of recovery, patient and healthcare staff satisfaction, hemodynamic effects, complications, and time to discharge after the procedure.
Eligibility criteria
Qualifiers
Age 18 to 85 years
ASA physical status I-III
Scheduled for ERCP, gastroscopy, or colonoscopy
Disqualifiers
Refusal to participate in the study
Inability to communicate
Alcohol or substance abuse
Neuropsychiatric disease
Trial design
Treatments tested in this trial
- Dexmedetomidine
- Remifentanil